Rae JM - Search Results

1

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.

Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Weinshilboum RM, Fritcher EG, Nibbe AM, Desta Z, Nguyen A, Flockhart DA, Perez EA, Ingle JN. Goetz MP, et al. Among authors: rae jm. Breast Cancer Res Treat. 2007 Jan;101(1):113-21. doi: 10.1007/s10549-006-9428-0. Epub 2006 Nov 18. Breast Cancer Res Treat. 2007. PMID: 17115111

2

Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays.

Rae JM, Johnson MD, Lippman ME, Flockhart DA. Rae JM, et al. J Pharmacol Exp Ther. 2001 Dec;299(3):849-57. J Pharmacol Exp Ther. 2001. PMID: 11714868

3

Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism.

Rae JM, Soukhova NV, Flockhart DA, Desta Z. Rae JM, et al. Drug Metab Dispos. 2002 May;30(5):525-30. doi: 10.1124/dmd.30.5.525. Drug Metab Dispos. 2002. PMID: 11950782

4

Cytochrome P450 3A pharmacogenetics: the road that needs traveled.

Flockhart DA, Rae JM. Flockhart DA, et al. Among authors: rae jm. Pharmacogenomics J. 2003;3(1):3-5. doi: 10.1038/sj.tpj.6500144. Pharmacogenomics J. 2003. PMID: 12629575 No abstract available.

5

Sequence diversity and functional characterization of the 5'-regulatory region of human CYP2C19.

Arefayene M, Skaar TC, Zhao X, Rae JM, Tanus-Santos JE, Brinkmann U, Brehm I, Salat U, Nguyen A, Desta Z, Flockhart DA. Arefayene M, et al. Among authors: rae jm. Pharmacogenetics. 2003 Apr;13(4):199-206. doi: 10.1097/00008571-200304000-00004. Pharmacogenetics. 2003. PMID: 12668916

6

Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples.

Rae JM, Cordero KE, Scheys JO, Lippman ME, Flockhart DA, Johnson MD. Rae JM, et al. Pharmacogenetics. 2003 Aug;13(8):501-7. doi: 10.1097/00008571-200308000-00008. Pharmacogenetics. 2003. PMID: 12893988

7

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.

Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA. Stearns V, et al. Among authors: rae jm. J Natl Cancer Inst. 2003 Dec 3;95(23):1758-64. doi: 10.1093/jnci/djg108. J Natl Cancer Inst. 2003. PMID: 14652237 Clinical Trial.

8

Evaluation of novel epidermal growth factor receptor tyrosine kinase inhibitors.

Rae JM, Lippman ME. Rae JM, et al. Breast Cancer Res Treat. 2004 Jan;83(2):99-107. doi: 10.1023/B:BREA.0000010702.10130.29. Breast Cancer Res Treat. 2004. PMID: 14997040 Free article.

9

Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen.

Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, Weatherman RV, Desta Z, Flockhart DA, Skaar TC. Johnson MD, et al. Among authors: rae jm. Breast Cancer Res Treat. 2004 May;85(2):151-9. doi: 10.1023/B:BREA.0000025406.31193.e8. Breast Cancer Res Treat. 2004. PMID: 15111773 Free article.

10

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.

Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes DF, Flockhart DA. Jin Y, et al. Among authors: rae jm. J Natl Cancer Inst. 2005 Jan 5;97(1):30-9. doi: 10.1093/jnci/dji005. J Natl Cancer Inst. 2005. PMID: 15632378

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

152 results

Search Page